

# COVID-19 vaccine immunization schedule

Updated September 2022



**COVID-19 vaccine immunization schedule**

Supplier	Recipient age	Immunization Schedule				Product	Preparation instructions BUD
		Primary series dose	No. of doses in primary series	Booster dose	Booster interval since last dose		
Interval between doses							
Moderna	6 mo – 5 y	25 mcg (0.25 mL)	2 <sup>a</sup> or 3 <sup>b</sup> • D1 to D2: ≥ 4 <sup>b</sup> -8 <sup>c</sup> wks • D2 to D3: ≥ 4 wks	Not authorized	NA	<b>Blue vial cap with magenta border</b> (NDC: 80777-279-99) • Primary series only (monovalent) • 25 mcg/0.25 mL	• Do not dilute • Discard 12 h after first puncture
	6 – 11 y	50 mcg (0.5 mL)	2 <sup>a</sup> or 3 <sup>b</sup> • D1 to D2: ≥ 4 <sup>b</sup> -8 <sup>c</sup> wks • D2 to D3: ≥ 4 wks	Not authorized	NA	<b>Dark blue vial cap with purple border</b> (NDC: 80777-277-99) • Primary series only (monovalent). <i>Labeling still states for, “booster doses only.” This product used to be used as a booster dose in adults and for the primary series in patients 6-11 y old – use in this pediatric population is now the only approved use for this product following EUA revisions and EUA for bivalent booster in adults.</i> • 50 mcg/0.5 mL	• Do not dilute • Discard 12 h after first puncture
	12-17 y	100 mcg (0.5 mL)	2 <sup>a</sup> or 3 <sup>b</sup> • D1 to D2: ≥ 4 <sup>b</sup> -8 <sup>c</sup> wks • D2 to D3: ≥ 4 wks	Not authorized	NA	<b>Red vial cap with light blue border</b> (NDC: 80777-273-99, 80777-273-98) • Primary series only (monovalent) • 100 mcg/0.5 mL	• Do not dilute • Discard 12 h after first puncture
	≥ 18 y	100 mcg (0.5 mL)	2 <sup>a</sup> or 3 <sup>b</sup> • D1 to D2: ≥ 4 <sup>b</sup> -8 <sup>c</sup> wks • D2 to D3: ≥ 4 wks	<b>Bivalent booster</b> 25 mcg original, 25 mcg Omicron BA.4/BA.5 [50 mcg (0.5 mL) total]	<b>Last dose*: ≥ 2 mos</b> <i>*Last dose includes either the final dose in the primary vaccine series in patients who have <u>not</u> yet received a booster or the last monovalent booster.</i>	<b>Red vial cap with light blue border</b> (NDC: 80777-273-99, 80777-273-98, 80777-100-99 <sup>d</sup> , 80777-100-98 <sup>d</sup> ) • Primary series only (monovalent) • 100 mcg/0.5 mL <b>Dark blue vial cap with gray border</b> (NDC: 80777-282-99) • Booster dose only (bivalent) • 50 mcg/0.5 mL	• Do not dilute • Discard 12 h after first puncture
Pfizer	6 mo – 4 y	3 mcg (0.2 mL)	3 <sup>a,b</sup> • D1 to D2: ≥ 3 <sup>b</sup> -8 <sup>c</sup> wks • D2 to D3: ≥ 8 wks	Not authorized	NA	<b>Maroon vial cap with maroon border</b> (NDC: 59267-0078-4) • Primary series only (monovalent) • 3 mcg/0.2 mL	• Dilute with 2.2 mL sterile 0.9% sodium chloride injection • BUD: 12 h after dilution
	5 – 11 y	10 mcg (0.2 mL)	2 <sup>a</sup> or 3 <sup>b</sup> • D1 to D2: ≥ 3 <sup>b</sup> -8 <sup>c</sup> wks • D2 to D3: ≥ 4 wks	<b>Monovalent booster</b> 10 mcg (0.2 mL)	D2 to B1: ≥ 5 mos <sup>a</sup> D3 to B1: ≥ 3 mos <sup>b</sup>	<b>Orange vial cap with orange border</b> (NDC: 59267-1055-4) • Primary series and booster dose (monovalent) • 10 mcg/0.2 mL	• Dilute with 1.3 mL sterile 0.9% sodium chloride injection • BUD: 12 h after dilution
	≥ 12 y	30 mcg (0.3 mL)	2 <sup>a</sup> or 3 <sup>b</sup> • D1 to D2: ≥ 3 <sup>b</sup> -8 <sup>c</sup> wks • D2 to D3: ≥ 4 wks	<b>Bivalent booster</b> 15 mcg original, 15 mcg Omicron BA.4/BA.5 [30 mcg (0.3 mL) total]	<b>Last dose*: ≥ 2 mos</b> <i>*Last dose includes either the final dose in the primary vaccine series in patients who have <u>not</u> yet received a booster or the last monovalent booster.</i>	<b>Purple vial cap with purple border</b> (NDC: 59267-1000-3, 59267-1000-2, 0069-1000-03 <sup>d</sup> , 0069-1000-02 <sup>d</sup> ) • Primary series only (monovalent) • 30 mcg/0.3 mL <b>Gray vial cap with gray border</b> (NDC: 59267-1025-4, 59267-1025-3, 0069-2025-10 <sup>d</sup> , 0069-2025-25 <sup>d</sup> ) • Primary series only (monovalent) • 30 mcg/0.3 mL <b>Gray vial cap with gray border</b> (NDC: 59267-1401-1, 59267-1404-2) • Booster dose only (bivalent) • 30 mcg/0.3 mL	<b>Purple vial cap with purple border</b> • Dilute with 1.8 mL sterile 0.9% sodium chloride injection • BUD: 6 h after dilution <b>Gray vial cap with gray border (monovalent and bivalent products)</b> • Do not dilute • BUD: 12 h after puncture
Novavax	≥ 12 y	5 mcg (0.5 mL)	2 <sup>e</sup> • D1 to D2: 3-8 <sup>f</sup> wks	Not authorized	NA	<b>Multidose vial</b> (NDC: 80631-100-01) • Primary series only (monovalent) • 5 mcg/0.5 mL	• Do not dilute • Discard 6 h after first puncture

**Footnotes:** <sup>a</sup> For most people; <sup>b</sup> For those who are moderately or severely immunocompromised; <sup>c</sup> An 8 wk interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 mos-64 y, especially for males ages 12-39 years; <sup>d</sup> FDA-approved product; <sup>e</sup> No recommendations are available for using this vaccine in persons who are immunocompromised; patients with significant immunocompromising conditions were excluded from clinical studies; <sup>f</sup> An 8-wk interval may be considered to reduce the risk of myocarditis or pericarditis, extrapolated from mRNA vaccine data. **Abbreviations:** B = booster; BUD = beyond use date; D = dose; EUA = emergency use authorization; NA = not applicable



Vizient, Inc.  
290 E. John Carpenter Freeway  
Irving, TX 75062-5146  
(800) 842-5146



To learn more, please contact Center for Pharmacy  
Practice Excellence Evidence-Based Medicine  
Group at [pharmacyquestions@vizientinc.com](mailto:pharmacyquestions@vizientinc.com).

As the nation's largest member-driven health care performance improvement company, Vizient provides solutions and services that empower health care providers to deliver high-value care by aligning cost, quality and market performance. With analytics, advisory services and a robust sourcing portfolio, we help members improve patient outcomes and lower costs.